Skip to main content

“Falling for Psychedelics”


Original Author: Tracie White – Stanford Magazine

Link to full article.

A groundbreaking new era has dawned in the world of psychedelic research, capturing the imagination of scientists and the public alike. Substances like psilocybin, LSD, MDMA, and ketamine are stealing the spotlight as potential miracle treatments for mental health disorders such as PTSD, depression, addiction, and anxiety. The intrigue surrounding these mysterious, fast-acting drugs is fueled by their potential to offer life-changing relief in a fraction of the time traditional psychiatric medications take to work.

However, beneath the allure lies a concern about the addictive properties of some of these substances, as well as the risk of harrowing experiences like “bad trips.” Researchers at Stanford University are racing against time to unravel the secrets behind these drugs and develop evidence-based guidelines for their responsible use. The fear that the public and governments might rush ahead of scientific research and federal regulations looms large, potentially stalling the remarkable progress being made in the field.

The FDA has taken notice of the promising early trials and granted MDMA and psilocybin “breakthrough therapy” status, accelerating their development as treatments. Researchers are urging the public to hold their breath and give science the time it needs to reveal the true potential of psychedelic therapy before diving headlong into the unknown.